EMA Authorised: Invanz (ertapenem sodium) — Merck Sharp & Dohme B.V.

View source ↗

Summary

The European Medicines Agency authorised Invanz (ertapenem sodium) by Merck Sharp & Dohme B.V. for a range of infections including community-acquired, streptoco…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Bacterial Pneumonia
• Community-acquired Infection
• Gram-negative Bacterial Infection
• Staphylococcal Infection
• Streptococcal Infection
• Surgical Site Infection

Drugs mentioned

• Invanz (ertapenem)

Snippet

Status: Authorised. Therapeutic area: Community-Acquired Infections;Streptococcal Infections;Staphylococcal Infections;Gram-Negative Bacterial Infections;Surgical Wound Infection;Pneumonia, Bacterial. MAH: Merck Sharp & Dohme B.V.. Decision date: 21/11/2025